{"nctId":"NCT00918346","briefTitle":"Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation","startDateStruct":{"date":"2005-09"},"conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"count":43,"armGroups":[{"label":"Tafluprost 0.0015% preserved formulation","type":"EXPERIMENTAL","interventionNames":["Drug: Tafluprost 0.0015%"]},{"label":"Tafluprost 0.0015% unpreserved formulation","type":"EXPERIMENTAL","interventionNames":["Drug: Tafluprost 0.0015%"]}],"interventions":[{"name":"Tafluprost 0.0015%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 years or more\n* A diagnosis of open angle glaucoma or ocular hypertension\n* Prior use of prostaglandin(s)\n* Intra ocular pressure of 22-34 mmHg in at least one eye\n\nExclusion Criteria:\n\n* Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception\n* Previous participation in any clinical trial in which tafluprost was an investigational drug or use of contact lenses at screening or during the study\n* Presence of any abnormality or significant illness that could be expected to interfere with the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intraocular Pressures (IOPs) at Baseline","description":"IOPs at baseline: mean IOP values at four timepoints (worse eye)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.57","spread":"3.04"},{"groupId":"OG001","value":"22.98","spread":"3.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.86","spread":"2.79"},{"groupId":"OG001","value":"21.78","spread":"2.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.73","spread":"3.19"},{"groupId":"OG001","value":"21.51","spread":"2.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.77","spread":"3.02"},{"groupId":"OG001","value":"21.81","spread":"2.61"}]}]}]},{"type":"SECONDARY","title":"Overall and Time-wise Comparisons of IOP at Week 1","description":"The overall and time-wise, i.e. at 8:00, 12:00, 16:00 and 20:00, comparisons of IOP at week 1 (diurnal IOP and IOP value at given timepoint at 1 week minus corresponding value at baseline: unpreserved-preserved) were done using the RM ANCOVA model.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Time-wise IOPs at Week 4","description":"The time-wise, i.e. at 8:00, 12:00, 16:00 and 20:00, comparisons of IOP at week 4 (IOP value at given timepoint at 4 weeks minus corresponding value at baseline: unpreserved-preserved) were done using the RM ANCOVA model.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":null}]}]}]},{"type":"PRIMARY","title":"Intraocular Pressures (IOPs) at Week 1","description":"IOPs at week 1: mean IOP values at four timepoints (worse eye)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.43","spread":"2.11"},{"groupId":"OG001","value":"16.21","spread":"2.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.77","spread":"1.60"},{"groupId":"OG001","value":"15.72","spread":"1.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.23","spread":"1.73"},{"groupId":"OG001","value":"15.83","spread":"1.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.26","spread":"2.20"},{"groupId":"OG001","value":"16.16","spread":"2.08"}]}]}]},{"type":"PRIMARY","title":"Intraocular Pressures (IOPs) at Week 4","description":"IOPs at week 4: mean IOP values at four timepoints (worse eye)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.39","spread":"2.43"},{"groupId":"OG001","value":"16.80","spread":"3.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.30","spread":"2.46"},{"groupId":"OG001","value":"16.67","spread":"2.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.64","spread":"2.37"},{"groupId":"OG001","value":"16.71","spread":"2.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.21","spread":"1.91"},{"groupId":"OG001","value":"17.01","spread":"2.44"}]}]}]},{"type":"PRIMARY","title":"Primary Pharmacodynamic Variable Intention to Treat Efficacy Dataset: Change From Baseline in the Overall Diurnal Intraocular Pressure (IOP) at Week 4 (Worse Eye)","description":"Overall treatment difference at 4 weeks (unpreserved-preserved) evaluated using a repeated measurements analysis of covariance (RM ANCOVA) model.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":null}]}]}]},{"type":"PRIMARY","title":"Primary Pharmacodynamic Variable Per Protocol Efficacy Dataset: Change From Baseline in the Overall Diurnal Intraocular Pressure (IOP) at Week 4 (Worse Eye)","description":"Overall treatment difference at 4 weeks (unpreserved-preserved) evaluated using a repeated measurments analysis of covariance (RM ANCOVA) model.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":42},"commonTop":["Conjunctival hyperemia","Ocular hyperemia","Erythema of eyelid","Eye pruritus","Foreign body sensation"]}}}